Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review
- 1Department of Biomedical Sciences, National Chung Cheng University , ,
- 2Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital , ,
Abstract
Urothelial carcinoma (UC) is a dynamic malignancy characterized by a complex epigenetic landscape. Epigenetic modifications are pivotal in modulating the innate immune response, particularly within the tumor microenvironment (TME), where they profoundly influence natural killer (NK) cell function. Aberrant epigenetic regulation often promotes immune evasion by silencing activating ligands on tumor cells, thereby impairing NK cell-mediated cytotoxicity. Emerging epigenetic therapies, such as histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTis), offer significant potential to reprogram the immune landscape and restore anti-tumor immunity. Despite this promise, clinical implementation faces challenges, including the immunosuppressive nature of the TME, NK cell exhaustion, and complex manufacturing limitations. Combining epigenetic agents with NK cell-based immunotherapies represents a robust strategy to overcome these barriers and improve therapeutic outcomes. This review elucidates the epigenetic regulatory mechanisms in UC and emphasizes the necessity of personalized, biomarker-driven treatment strategies to optimize cancer immunotherapy outcomes.
Related
- 713 Vitamin B6-mediated lipid metabolic reprogramming as a strategy to restore antitumor T cell immunity in aging
- Gonadal remodelling in socially driven sex change is associated with novel and known sex genes, epigenetic reprogramming, and inflammation-mediated apoptosis.
- Ginseng-derived extracellular vesicles alleviate ulcerative colitis by regulating macrophage glycolytic reprogramming and H3K18la-mediated epigenetic modification
- 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
- Transcriptional reprogramming and epigenetic regulation in Paramecium caudatum: a new model for studying extreme germline DNA elimination
BibTeX
@article{kumari2026epigenetic,
title = {{Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review}},
author = {Himani Kumari and Chih-Chieh Chou and Yu-Ting Lee and Cheng-Huang Shen and Michael W. Y. Chan},
journal = {Experimental biology and medicine (Maywood, N.J.)},
year = {2026},
month = oct,
doi = {10.3389/ebm.2026.11373},
url = {https://europepmc.org/article/PMC/PMC13751542},
note = {CC BY},
}
RIS
TY - JOUR
TI - Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review
AU - Himani Kumari
AU - Chih-Chieh Chou
AU - Yu-Ting Lee
AU - Cheng-Huang Shen
AU - Michael W. Y. Chan
PY - 2026
DA - 2026/10/28
JO - Experimental biology and medicine (Maywood, N.J.)
DO - 10.3389/ebm.2026.11373
UR - https://europepmc.org/article/PMC/PMC13751542
AB - Urothelial carcinoma (UC) is a dynamic malignancy characterized by a complex epigenetic landscape. Epigenetic modifications are pivotal in modulating the innate immune response, particularly within the tumor microenvironment (TME), where they profoundly influence natural killer (NK) cell function. Aberrant epigenetic regulation often promotes immune evasion by silencing activating ligands on tumor cells, thereby impairing NK cell-mediated cytotoxicity. Emerging epigenetic therapies, such as histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTis), offer significant potential to reprogram the immune landscape and restore anti-tumor immunity. Despite this promise, clinical implementation faces challenges, including the immunosuppressive nature of the TME, NK cell exhaustion, and complex manufacturing limitations. Combining epigenetic agents with NK cell-based immunotherapies represents a robust strategy to overcome these barriers and improve therapeutic outcomes. This review elucidates the epigenetic regulatory mechanisms in UC and emphasizes the necessity of personalized, biomarker-driven treatment strategies to optimize cancer immunotherapy outcomes.
SN - 1535-3702
SN - 1535-3699
ER -